71186-53-3
71186-53-3 结构式
基本信息
5-Hydroxydecanoate sodium
Sodium 5-hydroxydecanoate
5-HYDROXYDECANOIC ACID SODIUM
5-HYDROXYDECANOIC ACID SODIUM SALT
5-Hydroxydecanoic acid sodium salt,5-hydroxydecanoate sodium salt
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-136615 | 5-羟基癸酸钠 5-Hydroxydecanoate sodium | 71186-53-3 | 25mg | 600元 |
| 2024/01/25 | HY-136615 | 5-羟基癸酸钠 5-Hydroxydecanoate sodium | 71186-53-3 | 10mM * 1mLin DMSO | 660元 |
| 2024/01/25 | HY-136615 | 5-羟基癸酸钠 5-Hydroxydecanoate sodium | 71186-53-3 | 50mg | 960元 |
常见问题列表
IC50: ~30 μM (K ATP )
5-Hydroxydecanoate (5-HD) treatment abolishs the beneficial effects of penehyclidine hydrochloride (PHC) preconditioning in anoxia/reoxygenation (A/R)‐induced injury in H9c2 cells. 5-Hydroxydecanoate blocks the inhibitory effect of PHC on Ca 2+ overload and ROS production. 5-Hydroxydecanoate promotes the release of Cyt-C from mitochondria into cytoplasm. 5-Hydroxydecanoate attenuats the anti-apoptotic effect of PHC. PHC treatment shows remarkably decreases levels of Bax and cleaved caspase-3, and increases levels of Bcl-2. 5-Hydroxydecanoate pretreatment reverses the effects of PHC on their expression levels. 5-Hydroxydecanoate blocks the effects of PHC on K ATP channels.
5-Hydroxydecanoate (100 μM) treatment abolishes the effects of ischemic preconditioning (IPC) on the contractile recovery and does not affect its effect on the contracture, lactate production, glycogenolysis and viable tissue in rats.